Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Inclusion Criteria: * Enrolled in Bristol-Myers Squibb GastroEsophageal Opdivo in Resected Patients with Residual Pathological Disease Patient Support Program (GEORge PSP) in Canada * Patients who have consented to the use of their de-identified data generated from information collected in the course of the GEORge PSP Exclusion Criteria: * Aged \<18 years * Did not receive concurrent chemoradiotherapy prior to surgery * Positive margins following resection * No residual disease following complete resection